logo
Honka's Log Cabin Kit Homes Are Made From "the Perfect Material"

Honka's Log Cabin Kit Homes Are Made From "the Perfect Material"

Yahoo12-03-2025

The Finnish prefab builder uses locally sourced spruce and pine, touting them for their performance in a range of climates.
Welcome to Prefab Profiles, an ongoing series of interviews with people transforming how we build houses. From prefab tiny houses and modular cabin kits to entire homes ready to ship, their projects represent some of the best ideas in the industry. Do you know a prefab brand that should be on our radar? Get in touch!
Since 1958, Honka has manufactured an astounding number of prefab log cabin kits—more than 90,000, claims the Karstula, Finland, company. Today, its work spans everything from a lodge in Finland's frigid Lapland region, to a luxury spa under the hot Kenyan sun, and a mountain resort in Japan blanketed in heavy humidity. According to the company, the geographical breadth of their work can be attributed, in part, to their use of solid natural wood. "We use pine and spruce sourced from PEFC-certified Finnish forests. Finnish pine grows slowly, which makes it one of the densest coniferous woods on Earth. It's the perfect material for building a house" in a variety of climates, says Honka U.S. representative Mark Jermano.
Here, Jermano explains more about what sets Honka's log cabin kits apart from other prefab homes.
What does your base model cost and what does that pricing include?
In the U.S., an estimated turn-key build for a Honka log home ranges from $400 to over $600 per square foot. The cost depends on the complexity of the design, site development costs, local codes, labor rates, and builder fees, as well as product selections.
What qualities make your prefab stand apart from the rest?
Custom Homes: We offer customizable, ready-made designs and fully custom homes that suit a client's needs and lifestyle.
Honka Fusion™: Our proprietary concept combines mass timber with other building materials like glass, stone, and steel. The non-settling Honka Fusion CLT log allows us to build bold, diverse structures. It allows for the architectural appearance of a timber frame without the problems typically associated with timber frame construction. Honka Fusion houses are suited for modern architecture and urban settings.
Finnish Wood: Our log homes are designed and built to withstand harsh conditions in many climates and geographical circumstances. Our homes are created in Karstula, Finland, as a result of experience spanning more than 65 years, 90,000 projects, and numerous innovations.
Healthy Living: Honka houses provide a healthy living environment with organic building materials, high indoor air quality, and a welcoming atmosphere. Massive building logs retain the heat from the low sun during the winter, thereby enhancing the warmth and comfort during those cold winter months. Conversely, the logs retain the coolness of summer nights, allowing the home to quickly expel any trapped solar radiation and thereby creating a natural cooling effect without air conditioning. In addition, the logs filter the air and control the humidity inside the home, maintaining an average of 30 to 50 percent humidity, which is optimal for humans. Mass timber is also a fire-resistant material. A log house can also be a good choice in seismic areas.
See the full story on Dwell.com: Honka's Log Cabin Kit Homes Are Made From "the Perfect Material"Related stories:
Airstream's First All-Electric Travel Trailer—and Everything Else You Need to Know About This Week
2025 Pritzker Prize Winner Liu Jiakun Honored for His "Common Sense and Wisdom"
Are We Thinking About 3D-Printed Housing All Wrong?

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Hyland expands its presence in India with a new office in Hyderabad
Hyland expands its presence in India with a new office in Hyderabad

Business Upturn

timean hour ago

  • Business Upturn

Hyland expands its presence in India with a new office in Hyderabad

This marks a significant milestone in the company's global expansion strategy; enables access to technical expertise while strengthening the company's ability to serve customers globally NEW DELHI and HYDERABAD, India , June 10, 2025 /PRNewswire/ — Hyland, the pioneer of The Content Innovation Cloud™, is celebrating the official opening of its new office in Hyderabad , marking a significant milestone in the company's global expansion strategy, and mission to deliver breakthrough innovations to customers across the Asia Pacific region. The grand opening ceremony, held on 9 June 2025 , was graced by the presence of the US Consul General for Hyderabad , Ms. Jennifer Larson . Located in the heart of Hyderabad's prestigious Hitech City, the new facility represents Hyland's strategic investment in advancing The Content Innovation Cloud and accelerating customer success throughout Asia Pacific . This expansion positions the company to leverage the region's exceptional talent pool to drive next-generation innovations that transform how organizations manage, process, and unlock value from their content. ' Hyderabad's world-class technology ecosystem makes it the ideal location to advance The Content Innovation Cloud and deliver transformative solutions to our Asia Pacific customers,' said Tim McIntire , CTO at Hyland. 'This expansion directly supports our innovation agenda, enabling us to develop cutting-edge capabilities that help customers streamline operations, enhance productivity, and drive digital transformation. We're honored to have US Consul General Jennifer Larson join us for this momentous occasion, highlighting the power of US-India partnerships in advancing technological innovation.' The Hyderabad office will serve as a hub for innovation and customer success, housing critical functions focused on advancing The Content Innovation Cloud and delivering exceptional customer outcomes. This will drive product development, enhance customer enablement programs, and expand support capabilities to ensure Asia Pacific customers maximize value from Hyland's platform and solutions. The new facility is actively recruiting top talent to fuel Hyland's innovation engine across several key areas: Software Development professionals to architect and build next-generation capabilities within The Content Innovation Cloud to architect and build next-generation capabilities within The Content Innovation Cloud Professional Services specialists to accelerate customer implementations and drive successful digital transformation initiatives to accelerate customer implementations and drive successful digital transformation initiatives Customer Success coordinators to ensure customers achieve measurable business outcomes and maximize their return on investment to ensure customers achieve measurable business outcomes and maximize their return on investment Cloud and Technical Support experts to deliver world-class support and optimize customer experiences across cloud environments Hyland's new Hyderabad office joins its existing Kolkata location, reinforcing the company's global reach while creating significant employment opportunities, driving growth and customer success across the APAC region. To explore Hyland career opportunities in India , please visit the company's careers page at About Hyland Hyland empowers organizations with unified content, process and application intelligence solutions, unlocking profound insights that fuel innovation. Trusted by thousands of organizations worldwide, including many of the Fortune 100, Hyland's solutions fundamentally redefine how teams operate and engage with those they serve. For more information on Hyland, our products and solutions, please visit Photo: View original content to download multimedia: Disclaimer: The above press release comes to you under an arrangement with PR Newswire. Business Upturn takes no editorial responsibility for the same.

Zen Technologies shares in focus after introducing Four-Barrel Rotary Machine Gun
Zen Technologies shares in focus after introducing Four-Barrel Rotary Machine Gun

Business Upturn

timean hour ago

  • Business Upturn

Zen Technologies shares in focus after introducing Four-Barrel Rotary Machine Gun

Zen Technologies shares are in focus today after introducing its Four-Barrel Rotary Machine Gun, designed for counter-drone and high-intensity combat operations. The weapon features a rapid firing rate of up to 3,500 rounds per minute and an electronically operated firing mechanism, positioning it as a cutting-edge solution in modern warfare. Zen Technologies (@ZenTechnologies) Four-Barrel Rotary Machine Gun Featuring a firing rate of up to 3,500 rounds/min and dependable electronic operation, it stands as the premier weapon for counter-drone operations and intense combat scenarios. — Alpha Defense™🇮🇳 (@alpha_defense) June 10, 2025 The stock opened at ₹2,030.90 and touched an intraday high of ₹2,057.90, before slipping to a low of ₹2,015.00. It remains significantly below its 52-week high of ₹2,627.00 but well above the 52-week low of ₹945.35. As of 11:50 AM, the shares were trading 0.56% higher at Rs 2,025.00. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at

Emulate Launches AVA™ Emulation System to Accelerate Drug Development With First-of-its-Kind High-Throughput Organ-Chip Platform
Emulate Launches AVA™ Emulation System to Accelerate Drug Development With First-of-its-Kind High-Throughput Organ-Chip Platform

Business Wire

timean hour ago

  • Business Wire

Emulate Launches AVA™ Emulation System to Accelerate Drug Development With First-of-its-Kind High-Throughput Organ-Chip Platform

BOSTON--(BUSINESS WIRE)--Emulate, Inc., the world leader in Organ-on-a-Chip technology, today announced the commercial launch of the AVA™ Emulation System, a self-contained instrument that cultures, incubates, and images up to 96 independent Organ-Chip samples in a single run. AVA delivers an unprecedented magnitude of in vivo -level insights faster than animal models while cutting consumable costs four-fold and in-lab labor by half compared to current generation technologies. These transformative capabilities give the pharmaceutical industry the practical means to pivot beyond animal testing and into truly human-relevant territory. With the FDA targeting animal studies to become 'the exception rather than the norm,' the need for proven human models is urgent. Emulate's Liver-Chip S1—the first and only Organ-Chip admitted to the FDA's ISTAND program. Share 'AVA gives scientists unprecedented experimental capacity with the biological depth of live human tissue—something no other platform can match,' said Jim Corbett, Chief Executive Officer at Emulate. 'By combining Emulate's proven Organ-on-a-Chip technology with high-throughput consumables, automated imaging, and streamlined workflows in one benchtop unit, AVA lets teams ask bigger questions earlier and move the right drug candidates forward faster.' AVA Emulation System: Three Instruments in One AVA is the first self-contained Organ-on-a-Chip workstation to fuse high-throughput microfluidic tissue culture, full environmental control, and real-time imaging into a single, compact benchtop unit. Key performance gains include: Expanded experimental power – 96 independent Organ-Chip samples in a single run enable researchers to achieve microplate-level scale of their Organ-Chip experiments, enabling side-by-side comparison of dozens of compounds, doses, or stimuli. Lower operating costs – AVA achieves a four-fold drop in consumable spend and up to 50% fewer cells and media per sample compared to previous generation technology. Time & labor savings – Hands-on, in-lab time is reduced by more than half, thanks to automated microscopy, remote monitoring, and the revolutionary new Chip-Array™ consumable that integrates 12 independent Organ-Chips into an SBS format for streamlined workflows with multichannel pipettes and automated liquid handlers. AI-ready datasets – A typical 7-day experiment can generate >30,000 time-stamped data points from daily imaging and effluent assays, with post-takedown omics pushing the total into the millions—providing a rich, multi-modal foundation to feed machine-learning pipelines for target discovery, lead optimization, and safety prediction. A Timely Answer to Shifting Regulations With the FDA targeting animal studies to become 'the exception rather than the norm,' the need for proven human models is urgent. Emulate's Liver-Chip S1—the first and only Organ-Chip admitted to the FDA's ISTAND program—has already outperformed animals, showing 87% sensitivity and 100% specificity for drug-induced liver injury in a 2022 Communications Medicine study. AVA now scales that level of human relevance across discovery, efficacy, and toxicology screens, accelerating safer therapies through the pipeline. 'Moving towards reduction and in some cases replacement of animal models demands both biological fidelity and throughput,' noted Dr. Lorna Ewart, Emulate Chief Scientific Officer. 'AVA meets those dual requirements, empowering teams to rank-order lead candidates, pinpoint off-target toxicities, and advance safer therapies with unprecedented speed and confidence.' Broad Impact Across Industries In biopharma, this type of reduction and replacement is already a reality. A leading pharmaceutical company has demonstrated the power of implementing Organ-Chips into their development pipeline when one of their scientists saved millions of dollars and years of development time by using Emulate Liver-Chips ahead of non-human primates to screen lipid-nanoparticle (LNP) candidates. AVA's leap in throughput of predictive human biology stands to benefit not only biopharma but a wide spectrum of sectors that currently rely on inaccurate animal testing. Large pharmaceutical pipelines can now run comparable screens in a single AVA experiment, while smaller biotech teams gain enterprise-level capacity without adding headcount or infrastructure. Beyond therapeutics, contract research organizations, consumer-product companies, and environmental agencies can harness AVA to evaluate industrial chemicals, food additives, and cosmetic ingredients under human-relevant conditions—bringing faster, more ethical safety and efficacy decisions to market-driven and regulatory programs alike. Availability Global orders are open immediately. For pricing or demonstrations, please submit a request here. About Emulate Emulate, Inc. is the pioneer of Organ-on-a-Chip technology, enabling researchers to accurately replicate human tissue function and disease biology through next generation in vitro models. From target discovery to IND submission, Emulate aims to ignite a new era in human health research—one that reduces animal testing, cuts drug development costs, and accelerates the delivery of life-saving treatments. Emulate's Organ-Chip platforms, consumables, and organ models help the world's leading pharmaceutical, biotech, and academic teams generate human-relevant data that advance safer, more effective therapies. Learn more at

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store